Beginner | ESA | Schedule | OPD
Seminars | Atlas | Recent | Links
ÀϽÃ: 2015³â 9¿ù 12ÀÏ - 13ÀÏ
Àå¼Ò: È«Àºµ¿ ±×·£µå Èúư È£ÅÚ
 1. Debate on endoscopic management of lower GI neoplasia
 1. Debate on endoscopic management of lower GI neoplasia
¼øÃµÇâ´ëÇб³ °íºÀ¹Î ¼±»ý´Ô²²¼´Â ¸Å¿ì ÁÁÀº Áõ·ÊµéÀ» º¸¿©ÁÖ¸é¼ unclear pit pattern µîÀ» º¸À̴ ȯÀÚ¿¡¼ EUS¸¦ Ãß°¡ÇÏ¿© ½É´Þµµ ¿¹Ãø·üÀ» ³ôÀÏ ¼ö ÀÖ¾ú´Ù°í ¹ßÇ¥ÇÏ¿´½À´Ï´Ù. Àú´Â EUS îñ ¹é»ö±¤³»½Ã°æ, »ö¼Ò³»½Ã°æ, È®´ë³»½Ã°æ µîÀÇ ¼Ò°ßÀ» ¸ðµÎ È®º¸ÇÏ¿´±â ¶§¹®¿¡ ±× »óȲ¿¡¼ EUSÀÇ Á¤È®µµ´Â ¾ö¹ÐÈ÷ ¸»Çϸé EUSÀÇ Á¤È®µµ°¡ ¾Æ´Ï¶ó '¸ðµç °ÍÀ» Á¾ÇÕÇÑ Á¤È®µµ'¶ó°í ºÎ¸£´Â °ÍÀÌ Å¸´çÇÏ´Ù°í commentÇÏ¿´½À´Ï´Ù.
Keio ´ëÇÐÀÇ Naoki Hosoe´Â CLE (confocal laser endocytoscopy)¸¦ ¼Ò°³ÇÏ¿´½À´Ï´Ù. ¿¬¼¼´ë½ÅÃ̼¼ºê¶õ½º º´¿ø°ú ºÐ´ç Â÷º´¿ø µî¿¡µµ µµÀԵǾú½À´Ï´Ù. ¾ÆÁ÷Àº ¿¬±¸´Ü°èÀÎ ¸ð¾çÀÔ´Ï´Ù.
CLE has been first reported in 2004. Recently, it can be performed with two devices: one integrated into endoscope (e-CLE; Pentax), and one using a mini-probe through the scope (p-CLE; Cellvizio, France). CLE is based on tissue illumination with a low-power laser with subsequent detection of the fluorescence of light reflected from the tissue through a pinhole. Confocal imaing can be based on tissue reflectance or fluorescence. The fluorescent contrast agents most commonly used for CLE can be administered intravenously (fluorescein sodium, AK Fluor; Akorn Pharmaceutical, Lake Forest, Ill) or topically (Acriflavin; Sigma Pharmaceuticals, Clayton, Victoria, Australia), tetracycline, or cresyl violet (AnaSpec, Inc, San Jose, CA) through a spraying catheter."
°è¸í´ëÇб³ÀÇ ±èÀº¼ö ¼±»ý´ÔÀº screeningÀ» Çϸé 10 mm ÀÌÇÏÀÇ rectal NE tumorÀÇ ºñÀ²ÀÌ ÇöÀúÈ÷ ³ô¾ÆÁø´Ù´Â À̾߱â·Î °ÀǸ¦ ½ÃÀÛÇϼ̽À´Ï´Ù.
³»½Ã°æÀû Ä¡·á¹æ¹ýÀº ´Ù¾çÇѵ¥ ESD¿Í modified EMRÀÇ ¼ºÀûÀÌ ºñ½ÁÇÏ´Ù´Â Á¡À» ÀçÄ¡ÀÖ´Â ½½¶óÀ̵å·Î ½±°Ô º¸¿©Áּ̽À´Ï´Ù. µ¿°æ¾Ï¼¾ÅÍÀÇ ÀϺ»ÀÎ ÀÇ»ç´Â rectal carcinoid¸¦ ESDÇÒ Çʿ䰡 ¾ø´Ù°í comment ÇÏ¿´½À´Ï´Ù (¾à°£ °Ç¹æÁø ÀÚ¼¼·Î... »ßµüÇÏ°Ô ¼¼...).
NCCN guideline (2015)¿¡¼´Â "<1cm, No follow-up reguired"·Î µÇ¾î ÀÖ°í, ¿¬¼¼´ë ¿¬±¸(Kim DH. Digest Dis Sci 2014)¿¡µµ À§ÇèÀÎÀÚ°¡ ¾ø´Â ȯÀÚ¿¡¼ intensive surveillance°¡ ÇÊ¿äÇÏÁö ¾Ê´Ù°í ¾ð±ÞµÇ¾î ÀÖ½À´Ï´Ù.
±èÀº¼ö ¼±»ý´ÔÀº 5 mm grade 1 rectal NE tumorÀÇ EMR Á¶Á÷¿¡¼ lymphatic invasionÀÌ ÀÖ¾î ¼ö¼úÀ» ±ÇÇÏ¿´°í local lymph node metastasis°¡ ÀÖ¾ú´ø Áõ·Ê¸¦ ¼Ò°³Çϼ̽À´Ï´Ù. ¼¿ï¾Æ»êº´¿ø¿¡¼´Â Á÷Àå À¯¾ÏÁ¾ ³»½Ã°æÄ¡·á ÈÄ Á÷Àå¿· ¸²ÇÁÀýÀÌ ÃµÃµÈ÷ (7³â) Ä¿Áø °ÍÀ» ¹ß°ßÇÏ°í ¼ö¼úÇϱ⵵ Çß½À´Ï´Ù (Kim SH. Intest Res 2015). Áï ÀüÀ̰¡ À־ ¸Å¿ì õõÈ÷ ÀÚ¶õ´Ù´Â °ÍÀÔ´Ï´Ù.
°í¹ÎÀÌ ¾Æ´Ò ¼ö ¾ø½À´Ï´Ù. ³»½Ã°æÀ¸·Î Àß ÀýÁ¦µÈ 1 cm ÀÌÇÏÀÇ ÀÛÀº À¯¾ÏÁ¾ÀÇ º´¸®°Ë»ç¿¡¼ À§ÇèÀÎÀÚ°¡ ¾øÀ¸¸é ÃßÀû°üÂûÀ» ÇÏÁö ¸»ÀÚ´Â °¡À̵å¶óÀΰú ¿¬±¸°¡ °è¼Ó ¹ßÇ¥µÇ°í ÀÖ½À´Ï´Ù. ±×·±µ¥ ÃßÀû°üÂû ´ë»óÀÌ ¾Æ´Ñ ȯÀÚ¿¡¼ °£È¤ ÀüÀÌ(metastasis)°¡ ¹ß°ßµË´Ï´Ù. 5³â ÀÌÈÄ¿¡ ¹ß°ßµÇ´Â °æ¿ìµµ ÀÖ½À´Ï´Ù. µµ´ëü ´©±¸¸¦ ¾ðÁ¦±îÁö ÃßÀû°üÂû ÇÏ¿©¾ß ÇÒ±î¿ä? 1¸íµµ ³õÄ¡Áö ¾ÊÀ¸·Á¸é ³Ê¹« ¸¹Àº »ç¶÷ÀÌ ³Ê¹« ¸¹Àº °Ë»ç¸¦ ¹Þ¾Æ¾ß ÇÕ´Ï´Ù. Risk benefit ¿¬±¸°¡ ÇÊ¿äÇÏ´Ù°í »ý°¢µË´Ï´Ù. ¾ÆÁ÷ ¸íÈ®È÷ Á¤¸®µÇÁö ¸øÇÑ À̽´ÀÔ´Ï´Ù.
 2. Management of technically difficult endoscopic submucosal dissection for colorectal tumors - Shiro Oka (˪ ò¤ÕÍ, Hiroshima University)
 2. Management of technically difficult endoscopic submucosal dissection for colorectal tumors - Shiro Oka (˪ ò¤ÕÍ, Hiroshima University)
Oka ¼±»ý´ÔÀÇ Hiroshima ´ëÇÐÀº ÀϺ» ´ëÀå³»½Ã°æ°èÀÇ º¸½ºÀÎ Tanaka ¼±»ý´ÔÀÌ °è½Ê´Ï´Ù. ±×·¡¼ÀÎÁö colon ESD Áõ·Ê°¡ ¸Å¿ì ¸¹¾Ò½À´Ï´Ù. »óȲ¿¡ µû¶ó ´Ù¾çÇÑ Àü·«À» »ç¿ëÇϰí ÀÖ¾ú½À´Ï´Ù.
È¿À²ÀûÀÎ ½Ã¼úÀ» À§ÇÏ¿© µÎ °¡Áö ¹æ¹ýÀ» »ç¿ëÇÑ´Ù°í ÇÕ´Ï´Ù. (1) Single use splitting tube (single balloon overtube, sigle balloon enteroscopy technique°ú ºñ½ÁÇÏ¿´½À´Ï´Ù), (2) Needle-in technique using Dual knife¿´½À´Ï´Ù.
Á¦°Ô´Â Needle-in techniqueÀÌ ÀλóÀûÀ̾ú½À´Ï´Ù. Fibrosis°¡ ÀÖÀ» ¶§ È¿°úÀûÀ̶ó°í ÇÕ´Ï´Ù.
 3. Molecular imaging and theranostics for GI cancers - Jung-Joon Min (Department of Nuclear Medicine, Chonnam National University Hwasun Hospital)
 3. Molecular imaging and theranostics for GI cancers - Jung-Joon Min (Department of Nuclear Medicine, Chonnam National University Hwasun Hospital)
Precision medicine - °³ÀÎ À¯ÀüÀÚ Á¤º¸¿¡ ±Ù°ÅÇÑ °³º°ÈµÈ Ä¡·á
Theranostics - Targeted therapeutic°ú Companion diagnostic¸¦ ÇÕÇÑ °³³äÀÌ´Ù.
Repebody is a binding scaffold based on variable lymphocyte receptors, which are nonimmunoglobulin antibodies composed of leucine-rich repeat modules in jawless vertebrates. Rapebody can be developed against variety of epitopes by module engineering. In this study, EGFR-specific repebody (RBEGFR) was developed to visualize the status of receptor expression and to prevent ligand binding that may inhibit autophosphorylation and downstream intracellular signaling.
ÇÙÀÇÇаú ¼±»ý´Ô²²¼ ³»½Ã°æÇÐȸ¿¡¼ °ÀÇÇÑ Á¡ÀÌ ÀλóÀûÀ̾ú½À´Ï´Ù. ƯÈ÷ ¼Òȱ⳻°ú ÀÌ¿Ï½Ä ±³¼öÀÇ µµ¿òÀÌ ÄÇ´Ù°í ¸î Â÷·Ê À̾߱â Çϼ̽À´Ï´Ù. Àü³²´ëÇб³¿¡¼´Â ¿©·¯ Àü¹®°¡ »çÀÌÀÇ colloborationÀÌ Àß µÇ°í ÀÖ´Â °Í °°½À´Ï´Ù. ºÎ·¯¿î ÀÏÀÔ´Ï´Ù.
 4. Case-based discussion (°¡Å縯´ëÇб³ ¹ÚÀç¸í)
 4. Case-based discussion (°¡Å縯´ëÇб³ ¹ÚÀç¸í)
µÎ °³ÀÇ ¼±Á¾À¸·Î ÀǷڵǾúÀ½. AFI¿¡¼ µÎ º´¼Ò°¡ ¿¬°áµÇ¾î º¸¿©¼ single piece·Î ESD¸¦ ÇÏ¿´°í 8 cm Á¡¸·¾Ï º´¸®ÇÐÀû ¿ÏÀüÀýÁ¦·Î ³ª¿Ô½À´Ï´Ù. ¹ÚÀç¸í ¼±»ý´ÔÀº AFI°¡ multiple cancer¸¦ ¹ß°ßÇϴµ¥ µµ¿òµÈ´Ù´Â ¿¬±¸°á°ú¸¦ ¹ßÇ¥ÇÑ ¹Ù ÀÖ½À´Ï´Ù. Superficial spreading type º´¼Ò°¡ 8 cmÀ̰í Á¶Á÷°Ë»ç°¡ adenocarcinoma¿´´Ù¸é °ú¿¬ ESD¸¦ ÇßÀ»Áö ±Ã±ÝÇß½À´Ï´Ù. Àú´Â ¼ö¼úÀ» º¸³¾ °Í °°½À´Ï´Ù. Pre-ESD diagnostic group°ú post-ESD diagnostic groupÀÇ Â÷À̰¡ Áß¿äÇÒ °Í °°½À´Ï´Ù. ÀÌ È¯ÀÚ´Â pre-ESD diagnostic groupÀÌ adenoma¿´±â¿¡ ESD°¡ ¼±ÅÃµÈ °ÍÀÔ´Ï´Ù. ESD °ü·Ã ÀڷḦ ÀÐÀ» ¶§¿¡´Â ÀÌ Á¡À» ÁÖÀÇÇØ¾ß ÇÒ °Í °°½À´Ï´Ù.
Åä¿äÀÏ Àú³á Gala Dinnerµµ ÁÁ¾Ò½À´Ï´Ù.
 5. Treatment Strategy and Limitations of Standard ESD (2015-9-13 (ìí) 7:30-8:10 Breakfast with the Experts ¼¼¼Ç)  - IDEN 2015
 5. Treatment Strategy and Limitations of Standard ESD (2015-9-13 (ìí) 7:30-8:10 Breakfast with the Experts ¼¼¼Ç)  - IDEN 2015 
 6. Do we have to be more aggressive in therapeutic endoscopy?
 6. Do we have to be more aggressive in therapeutic endoscopy? 
1) Current stuatus of NOTES in Europe - Silvana Perretta (University of Strsabourg, France)
NOTES ȤÀº advanced endoscopy¶ó´Â À̸§À» ½ÃÇàµÇ´Â ¸¹Àº ½Ã¼úÀ» º¸¿©ÁÖ¾ú½À´Ï´Ù. Àú´Â ¾Æ·¡ ½½¶óÀ̵尡 °¡Àå ÁÁ¾Ò½À´Ï´Ù. ±×·¸½À´Ï´Ù. °ú°Å ¼ö¼úÇÏ´ø º´ÀÌ »ó´ç¼ö ³»½Ã°æÀ¸·Î Ä¡·áÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ±×·¯³ª, ¼ö¼úÇÏ´ø º´ÀÌ ¸ðµÎ ³»½Ã°æ Ä¡·á·Î ¹Ù²ð °Í °°Áö´Â ¾Ê½À´Ï´Ù. µÇ´Â °ÍÀÌ ÀÖ°í ¾È µÇ´Â °ÍÀÌ ÀÖ½À´Ï´Ù. Áß¿ëÀ» ÁöŰ´Â °ÍÀÌ Áß¿äÇÒ µí ÇÕ´Ï´Ù. ÀÓ»ó°¡ÀÇ ÀÔÀå¿¡¼´Â...
Anubiscope
Confocal endomicroscopy tuided myotomy. º´ÀÌ ¾îµð¿¡ ÀÖ´ÂÁö ¾Ë ¼ö ÀÖ´Ù.
The third space
2) Broadening the applicability of ESD for EGC, technique or indication? (¼ÛÈ£ÁØ, ¼¿ï¾Æ»êº´¿ø)
¼ÛÈ£ÁØ ¼±»ý´ÔÀº ESD indicationÀÇ intermediate area°¡ ÀÖ´Ù´Â Á¡À» °Á¶ÇÏ¿´½À´Ï´Ù. 100% µ¿ÀÇÇսôÙ.
¼ÛÈ£ÁØ ¼±»ý´ÔÀº ¾Æ·¡ »çÁøÀ» º¸¿©ÁÖ¸é¼ Áú¹®À» ´øÁö¼Ì½À´Ï´Ù. ´äÀº ÁÖÁö ¾Ê¾ÒÁö¸¸... ÁÂÃø´Â 48¼¼ ¿©ÀÚ signet ring cell carcinoma¿´°í ¿ìÃøÀº 56¼¼ ³²ÀÚ poorly differentiated adenocarcinoma¿´½À´Ï´Ù.
Á¦ ³ª¸§ÀÇ ´äÀ» »ý°¢ÇØ º¸¾Ò½À´Ï´Ù. ¸ÕÀú ¿ìÃø 56¼¼ ³²ÀÚÀÇ °æ¿ì´Â °£´ÜÇÕ´Ï´Ù. ¼ö¼úÀÔ´Ï´Ù. Poorly differentiated adenocarcinoma´Â signet ring cell carcinomaº¸´Ù ¿©·¯ ¸éÀÌ ÁÁÁö ¾Ê½À´Ï´Ù. °æ°è ÆÇÁ¤°ú ½É´Þµµ ÆÇÁ¤ÀÌ ¾î·Æ°í ¸²ÇÁÀý ÀüÀ̵µ ´Ù¼Ò ¸¹Àº µí ÇÕ´Ï´Ù. Poorly differentiated adenocarcinomaÀÇ °æ¿ì´Â °ÅÀÇ ÀÚµ¿ÀûÀ¸·Î ¼ö¼úÀ» º¸³»°í ÀÖ½À´Ï´Ù.
¹®Á¦´Â ÁÂÃø signet ring cell carcinomaÀÔ´Ï´Ù. Á¦ ÆÇ´ÜÀº ¿©ÀüÈ÷ ¼ö¼úÀÔ´Ï´Ù. Signet ring cell carcinomaµµ Ä¡·áÇØ º¸¸é »ý°¢º¸´Ù Å« °æ¿ì°¡ ¸¹½À´Ï´Ù. ¸²ÇÁÀý ÀüÀ̵µ ¾øÁö ¾Ê½À´Ï´Ù. ´Ù¸¸ ÃÖ±Ù ¿©·¯ ¹®Çå°ú Àü¹®°¡ Àǰ߰ú ÀúÈñÀÇ ºÐ¼®(2015³â ´ëÇѼÒȱâÇÐȸ¿¡ ÃÊ·ÏÀ» Á¦ÃâÇÏ¿´½À´Ï´Ù) µîÀ» °í·ÁÇÒ ¶§, 1 cm ÀÌÇÏÀÇ flatÇÑ signet ring cell carcinoma´Â ESD¸¦ °í·ÁÇÒ ¼ö ÀÖÀ» °Í °°´Ù´Â ´À³¦Àº °¡Áö°í ÀÖ½À´Ï´Ù. ¿¹»óµÇ´Â curative resection rate´Â 70% Á¤µµÀÔ´Ï´Ù. Non-curative resectionÀ̶ó´Â º´¸®°á°ú¶ó¸é ¹Ýµå½Ã ¼ö¼úÀ» ÇØ¾ß ÇÕ´Ï´Ù. ÁÂÃø 48¼¼ ¿©ÀÚ È¯ÀÚ¿¡ ´ëÇÑ ÀúÀÇ ÀǰßÀº "¼ö¼úÀ» ÃßõÇ쵂 clinical trial setting¿¡¼ ȤÀº ±×¿¡ ÁØÇÑ »óȲ¿¡¼ ESD¸¦ ½ÃÇàÇÒ ¼ö ÀÖ´Ù"ÀÔ´Ï´Ù. ÇöÀç±îÁö signet ring cell carcinoma¿¡ ´ëÇÑ ESD¸¦ Ç¥ÁØ Ä¡·á·Î »ý°¢ÇÏÁö´Â ¾Ê°í ÀÖ½À´Ï´Ù. ºñÇ¥ÁØ Ä¡·á¸¦ ȯÀÚ¿¡°Ô Àû¿ëÇÒ ¶§¿¡´Â ¸Å¿ì ÁÖÀÇÇØ¾ß ÇÕ´Ï´Ù.
3) Endoscopic management for stircure and leakage (ÀÌÇ×¶ô, ÇѾç´ëÇб³)
Long segment lye stricture¸¦ stentingÀ¸·Î Ä¡·áÇÑ »ç·Ê°¡ ÀλóÀûÀ̾ú½À´Ï´Ù. È޽Ľð£¿¡ ÀÌÇ×¶ô ¼±»ý´Ô²² ¹®ÀÇÇÑ ¹Ù 3 Áõ·Ê°¡ ÀÖ¾ú°í 2¸íÀº ¾ÆÁÖ Àß µÇ¾ú°í 1¸íÀº õ°øÀÌ ¹ß»ýÇÏ¿´´Ù°í ÇÕ´Ï´Ù. ´ÙÇེ·´°Ô õ°ø 1¸íÀº ºñ¼ö¼úÀû Ä¡·á·Î È£ÀüµÇ¾ú´Ù°í Çϳ׿ä.
FIstula ȤÀº perforationÀ» Ä¡·áÇÏ´Â ¿©·¯ optionÀ» ¼³¸íÇØ Áּ̽À´Ï´Ù.
ÀÌ Áß OTSC (over the scope clip device)´Â ÇöÀç ±¹³»¿¡¼ »ç¿ëÇÒ ¼ö ¾ø´Â °ÍÀ¸·Î ¾Ë°í ÀÖ½À´Ï´Ù. 1ȸ¿ëÀ¸·Î 100¸¸¿ø Âë Çߴµ¥¿ä... ³ª¸§ À¯¿ë¼ºÀÌ ÀÖ¾úÁö¸¸ ºñ½Î´Ù´Â ÀÌÀ¯·Î ´ç±¹¿¡¼ no ÇÑ °Í °°½À´Ï´Ù. ¾ÈŸ±î¿î ÀÏÀÌ °è¼ÓµË´Ï´Ù. ¿ì¸®³ª¶ó¿¡¼´Â ½Ñ Ä¡·á¸¦ Àß ÇÏ´Â °ÍÀÌ ÁÁÀº Àǻ簡 µÇ´Â Áö¸§±æÀÔ´Ï´Ù. Á¶±Ý¸¸ ºñ½Î¸é ¹Ù·Î no µË´Ï´Ù. ÀÌ·±...
 7. ³»½Ã°æÀû À¯¹®±Ù ÀýÁ¦¼ú. endoscopic pyloromyotomy (¿¬¼¼´ëÇб³ Á¤Çö¼ö)
  7. ³»½Ã°æÀû À¯¹®±Ù ÀýÁ¦¼ú. endoscopic pyloromyotomy (¿¬¼¼´ëÇб³ Á¤Çö¼ö)
POEM°ú °°Àº °³³äÀ» pylorus¿¡ Àû¿ëÇÑ ½Ã¼úÀÔ´Ï´Ù. °ú°Å¿¡ ´Ù¼Ò °¡º±°Ô ´Ù·ïÁö´ø pylorius°¡ ¾ÕÀ¸·Î´Â Áß¿äÇØÁú Àü¸ÁÀÔ´Ï´Ù.
2013³â Khashab µîÀÌ ´ç´¢º´¼º À§¸¶ºñ¿¡¼ ÃÖÃÊ·Î ½ÃÇàµÇ¾ú½À´Ï´Ù (Khashab. Gastrointest Endosc 2013). Á¤Çö¼ö ¼±»ý´ÔÀº ¼ö¼ú ÈÄ À§¸¶ºñ ȯÀÚ¿¡¼ ½ÃÇàÇÏ¿´½À´Ï´Ù. ¿¬¼¼´ëÇб³¿¡¼´Â Áö±Ý±îÁö ´ç´¢º´¼º À§¸¶ºñ¿Í ½ÄµµÀýÁ¦¼ú ÈÄ À§¸¶ºñ ȯÀÚ 12¸í¿¡¼ ½ÃÇàÇß´Ù°í ÇÕ´Ï´Ù. Mean emptying timeÀÌ 370ºÐ¿¡¼ 170ºÐÀ¸·Î 200ºÐ Á¤µµ ª¾ÆÁö´Âµ¥ Á¤»ó ¹üÀ§·Î µ¹¾Æ¿À´Â °æ¿ì´Â ¸¹Áö ¾Ê¾Ò½À´Ï´Ù.
Seohyun Lee(¼¿ï¾Æ»êº´¿ø)Àº ´ëÀå ESD¿¡¼ histologic lateral margin positivity¿¡ ´ëÇÑ Æ÷½ºÅÍ¿¡¼ lateral margin false positiveÀÇ ÀÌÀ¯¿Í À̸¦ ¸·±âÀ§ÇÑ tipÀ» ¼Ò°³ÇÏ¿´½À´Ï´Ù.
Jeong Wook Kim (Á߾Ӵ뺴¿ø)Àº hard sigmoid fecaloma¸¦ Coca-cola injection ÈÄ snaringÀ¸·Î Á¦°ÅÇÑ Áõ·Ê¸¦ ¼Ò°³ÇÏ¿´½À´Ï´Ù. ³¿»õ°¡ ¸¹ÀÌ ³µÀ» °Í °°½À´Ï´Ù.^^
In Ji Song (¿¬¼¼´ëº´¿ø)Àº ESD ÈÄ additional gastrectomy¿¡ ´ëÇÑ predictive modelÀ» ¼Ò°³Çß½À´Ï´Ù.
À§ fundusÀÇ 1 cm SMT¿¡ ´ëÇÏ¿© EUS ÈÄ ESD¸¦ ½ÃÇàÇÑ Áõ·Ê°¡ ¼Ò°³µÇ¾ú½À´Ï´Ù. Àú´Â 'À§ fundusÀÇ 1 cm SMT´Â EUS ÀûÀÀÁõÀÌ ¾Æ´Ï´Ù'´Â ÀǰßÀ» ¹àÇû½À´Ï´Ù. ¿©·¯ ¼±»ý´Ôµé²²¼ ¹Ý´ëÀǰßÀ» ¸»¾¸Çϼ̽À´Ï´Ù. ¿ÏÀüÈ÷ Äڳʿ¡ ¸ô¸° ´À³¦... ±×·±µ¥ ³î¶ó¿î °ÍÀº È޽Ľð£¿¡ ¶Ç ´Ù¸¥ ¿©·¯ ¼±»ý´Ôµé²²¼ Àú¸¦ ã¾Æ¿Í °Ý·ÁÇØ Á̴ּٴ °ÍÀÔ´Ï´Ù. Àú¿Í °°Àº ÀǰßÀ» °¡Áö°í °è½Å´Ù¸é¼... Àü¹®°¡ »çÀÌ¿¡¼µµ EUS´Â È£ºÒÈ£°¡ ¸í¹éÈ÷ °¥¸³´Ï´Ù. ÇÐȸÀå¿¡¼´Â EUS¸¦ »ç¶ûÇÏ´Â ¼±»ý´Ôµé¸¸ ¹ß¾ðÇϱ⠶§¹®¿¡ ±× Çʿ伺ÀÌ °ú´ëÆò°¡µÇÁö¸¸, ÇöÀåÀÇ ¿©·¯ °í¼öµéÀº ÇÐȸÀåÀÇ µé¶á ºÐÀ§±â¿¡ ÈÛ¾µ¸®Áö ¾Ê°í ¹¬¹¬È÷ ÀûÀýÇÑ ÀûÀÀÁõÀ» ÁöŰ°í °è½Å °Í °°½À´Ï´Ù. Âü ´ÙÇེ·¯¿î ÀÏÀÔ´Ï´Ù. Àú´Â ȯÀÚ¸¦ »ç¶ûÇÏÁö¸¸ EUS¸¦ »ç¶ûÇÏÁö´Â ¾Ê½À´Ï´Ù. ÇÊ¿äÇÒ ¶§ ÀÌ¿ëÇÒ »ÓÀÔ´Ï´Ù.
IDENÀÇ ¿©·¯ °ÀǸ¦ µéÀ¸¸é¼ Á¦°¡ ¹«Ã´ ³°Àº »ç¶÷ÀÌ µÇ¾î¹ö¸° ´À³¦À̾ú½À´Ï´Ù. Submucosal tunnelingÀ» ÀÌ¿ëÇÑ third space¿¡¼ ÀÏÇÏ´Â pioneerµéÀÌ Âü ¸¹´õ±º¿ä. ¹Ý¸é¿¡ Àú´Â 'first spaceÀÎ À§Á¡¸·¿¡¼ endoscopic submucosal dissection (ESD)À̶ó´Â »·ÇÏ°í ³°Àº ½Ã¼úÀ» ÇàÇÏ´Â Åð¹°'ÀÌ µÈ µíÇÑ ±âºÐÀ» ¶³Ä¡±â ¾î·Á¿ü½À´Ï´Ù. ÀÌ ÆÐ¹è°¨À» ¾î¶»°Ô ±Øº¹ÇØ¾ß ÇÒÁö... Àú¸¦ ã´Â ȯÀÚÀÇ 99.9%´Â first space¿¡¼ Ä¡·áÇÒ ¼ö ÀÖ°í, 0.1% ȤÀº ±× ÀÌÇÏ¿¡¼ third space Ä¡·á°¡ ÇÊ¿äÇÒ °Í °°½À´Ï´Ù. Third space´Â ¾î¼´Ù Çѹø µé¾î°¡°í Æò¼Ò¿¡´Â ±×³É first space¸¦ Áöų±î ÇÕ´Ï´Ù. Àú´Â ±×³É ´Ã ÇÏ´ø ESD¸¦ Á» ´õ Àß ÇÒ±î ÇÕ´Ï´Ù. Á¦¹ß ESD¸¦ ¹ö¸®Áö ¸»¾ÆÁÖ¼¼¿ä.
2015³â 6¿ù 20ÀϺÎÅÍ 21ÀϱîÁö ¼¿ï Grand Hilton È£ÅÚ¿¡¼ IDEN 2015ÀÌ ¿¸± °èȹÀ̾ú½À´Ï´Ù. Àú´Â ù ³¯ ù ¼¼¼Ç¿¡ °Àǰ¡ ÀÖ¾ú½À´Ï´Ù. ±×·¯³ª MERS »çÅ·ΠÀÎÇÏ¿© 9¿ù·Î Çà»ç°¡ ¿Å°ÜÁö¸é¼ Á¦ ¼¼¼ÇÀÌ »ç¶óÁ³½À´Ï´Ù. ¿Ü±¹ÀÎ ¿¬ÀÚµéÀÌ Âü¼®ÀÌ ºÒ°¡´ÉÇØÁ³±â ¶§¹®ÀÔ´Ï´Ù. °á±¹ Breakfast with the Experts ¼¼¼ÇÀ¸·Î º¯°æµÇ¾ú½À´Ï´Ù.